search
Back to results

Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (Best-C)

Primary Purpose

Hepatitis C, Chronic Hepatitis C

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Mailer
In-person recruitment
EHR Alert
Sponsored by
National Opinion Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Hepatitis C focused on measuring Hepatitis C, Chronic Hepatitis C, Screening

Eligibility Criteria

47 Years - 69 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Born 1945-1965

Exclusion Criteria:

  • Prior diagnosis of Hepatitis C

Sites / Locations

  • University of Alabama, Birmingham
  • Henry Ford Health System
  • Mt. Sinai Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Mt. Sinai

Henry Ford Health System

University of Alabama, Birmingham

Arm Description

Cluster randomization with EHR Alert intervention

Simple randomization with mailer intervention

Crossover randomization with in-person recruitment intervention

Outcomes

Primary Outcome Measures

Positive Hepatitis C Test
Positive diagnosis on a Hepatitis C test

Secondary Outcome Measures

Tested for Hepatitis C
Patient received a test for Hepatitis C

Full Information

First Posted
April 22, 2014
Last Updated
March 25, 2015
Sponsor
National Opinion Research Center
Collaborators
NORC at the University of Chicago, University of Alabama at Birmingham, Henry Ford Health System, Icahn School of Medicine at Mount Sinai, Centers for Disease Control and Prevention
search

1. Study Identification

Unique Protocol Identification Number
NCT02123212
Brief Title
Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C
Acronym
Best-C
Official Title
Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
February 2013 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Opinion Research Center
Collaborators
NORC at the University of Chicago, University of Alabama at Birmingham, Henry Ford Health System, Icahn School of Medicine at Mount Sinai, Centers for Disease Control and Prevention

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C) compares the effectiveness of the birth cohort HCV screening strategy with the current risk-based screening approach to detect previous unidentified persons with viral hepatitis C who receive health care in primary systems. The study involved three clinical sites, The University of Alabama, Birmingham; The Henry Ford Health System; and the Mount Sinai Medical Center, each of which developed an independent intervention to experimentally compare the number of positive Hepatitis C Virus (HCV) diagnoses found using the birth-cohort screening approach with that found using traditional risk-based screening, or standard of care strategies. Birth cohort testing is defined as the systematic recommendation of HCV antibody testing to any persons born during the years of 1945 to 1965 who do not have clinically documented evidence of a prior antibody test without regards to the patient's stated risk of exposure to the virus.
Detailed Description
The Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C (BEST-C) compares the effectiveness of the birth cohort HCV screening strategy with the current risk-based HCV screening approach to detect previously unidentified persons with viral hepatitis C who receive health care in primary care systems. BEST-C funded sites to implement birth-cohort testing in a clinic sample of primary care patients using an experimental design to compare the effect of birth-cohort testing on testing rates and identified prevalence between a case and a control sample. Additional data will be collected to assess linkage to care for those testing positive, feasibility, and acceptance of the new strategy by medical staff, cost effectiveness, and patient impact. The sites used three models to measure the net effect of change: One site used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cluster randomized cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study. A second site reached out directly to the patient using direct communication through the mail. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. This site used simple randomization of patients who used the health system in the past, met the definition of birth-cohort membership (born during 1945 to 1965) and had not previously tested positive for hepatitis C. The patients received up to 5 mailings including prepaid, lab registration forms that they were instructed to bring to an affiliated lab location for testing. A third site implemented a physican best practice alert into the Epic electronic health record system of their clinic setting. This site had the pop-ups enabled for Medical Assistants (MAs) who were asked to pend the lab to the order in the chart for the clinician. When MAs open the chart of an arrived, untested patient, they are alerted to pend the Hepatitis C antibody test order when entering patient vitals prior to the patient seeing the physician. When the clinician subsequently opened the same patient chart, the lab order was present in the orders section of the chart for signature and execution or deletion depending on the circumstances of the patient encounter. As a back-up pathway alerted the physician directly in the event that the MA bypassed or did not open the prompt. This alert details the CDC recommendations for age-based screening and links to the proper Hepatitis C antibody test order and diagnosis code for them to address with the patient. This site used a cluster randomized experimental design in which physicians and MA's from specific primary care practices were consented into the study. Experimental clusters received an education about HCV testing and the implemented best practice alert. Control clusters received only education about HCV testing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C, Chronic Hepatitis C
Keywords
Hepatitis C, Chronic Hepatitis C, Screening

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
29607 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Mt. Sinai
Arm Type
Experimental
Arm Description
Cluster randomization with EHR Alert intervention
Arm Title
Henry Ford Health System
Arm Type
Experimental
Arm Description
Simple randomization with mailer intervention
Arm Title
University of Alabama, Birmingham
Arm Type
Experimental
Arm Description
Crossover randomization with in-person recruitment intervention
Intervention Type
Other
Intervention Name(s)
Mailer
Intervention Description
Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
Intervention Type
Other
Intervention Name(s)
In-person recruitment
Intervention Description
UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
Intervention Type
Other
Intervention Name(s)
EHR Alert
Intervention Description
EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
Primary Outcome Measure Information:
Title
Positive Hepatitis C Test
Description
Positive diagnosis on a Hepatitis C test
Time Frame
Up to 16 weeks
Secondary Outcome Measure Information:
Title
Tested for Hepatitis C
Description
Patient received a test for Hepatitis C
Time Frame
Up to 16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
47 Years
Maximum Age & Unit of Time
69 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Born 1945-1965 Exclusion Criteria: Prior diagnosis of Hepatitis C
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David B Rein, Ph.D.
Organizational Affiliation
NORC at the University of Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama, Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Mt. Sinai Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22056542
Citation
Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, Patel N, Ward JW, Weinbaum CM. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012 Feb 21;156(4):263-70. doi: 10.7326/0003-4819-156-4-201202210-00378. Epub 2011 Nov 4.
Results Reference
background
PubMed Identifier
25595745
Citation
Smith BD, Yartel AK, Krauskopf K, Massoud OI, Brown KA, Fallon MB, Rein DB. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis. 2015 Apr 15;60(8):1145-52. doi: 10.1093/cid/civ002. Epub 2015 Jan 16.
Results Reference
background
PubMed Identifier
24776636
Citation
Jewett A, Garg A, Meyer K, Wagner LD, Krauskopf K, Brown KA, Pan JJ, Massoud O, Smith BD, Rein DB. Hepatitis C virus testing perspectives among primary care physicians in four large primary care settings. Health Promot Pract. 2015 Mar;16(2):256-63. doi: 10.1177/1524839914532291. Epub 2014 Apr 28.
Results Reference
background
PubMed Identifier
28288075
Citation
Federman AD, Kil N, Kannry J, Andreopolous E, Toribio W, Lyons J, Singer M, Yartel A, Smith BD, Rein DB, Krauskopf K. An Electronic Health Record-based Intervention to Promote Hepatitis C Virus Testing Among Adults Born Between 1945 and 1965: A Cluster-randomized Trial. Med Care. 2017 Jun;55(6):590-597. doi: 10.1097/MLR.0000000000000715.
Results Reference
derived

Learn more about this trial

Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C

We'll reach out to this number within 24 hrs